Balcinrenone|1850385-64-6|(AZD9977)-陌孚医药/Medlife

您当前的位置：

Balcinrenone (Synonyms: AZD9977)

目录号: PL07288 纯度: ≥99%

CAS No. :1850385-64-6

商品编号	规格	价格	会员价
PL07288-5mg	5mg	¥3090.91	请登录
PL07288-10mg	10mg	¥4821.82	请登录
PL07288-25mg	25mg	¥8530.91	请登录
PL07288-50mg	50mg	¥12240.00	请登录
PL07288-100mg	100mg	¥18298.18	请登录
PL07288-200mg	200mg	询价	询价
PL07288-500mg	500mg	询价	询价
PL07288-10mM*1mLinDMSO	10mM*1mLinDMSO	¥3944.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Balcinrenone
英文名称	Balcinrenone
英文别名	AZD9977;6C9UKZ0CYE;2-[(3S)-7-Fluoro-4-(3-oxo-4H-1,4-benzoxazine-6-carbonyl)-2,3-dihydro-1,4-benzoxazin-3-yl]-N-methylacetamide;2-[(3~{S})-7-fluoranyl-4-[(3-oxidanylidene-4~{H}-1,4-benzoxazin-6-yl)carbonyl]-2,3-dihydro-1,4-benzoxazin-3-yl]-~{N}-methyl-ethanamide;Azd 9977;GTPL11281;BDBM238159;DB15418;US9394291, 4a;FC1=CC2=C(N([C@H](CO2)CC(=O)NC)C(=O)C=2C=CC3=C(NC(CO3)=O)C=2)C=C1;2-{(3S)-7-Fluoro-4-[(3-oxo-3,
Cas No.	1850385-64-6
分子式	C₂₀H₁₈FN₃O₅
分子量	399.37
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Balcinrenone (AZD9977) 是一种有效的，选择性的，具有口服活性的盐皮质激素受体 (MR) 调节剂。Balcinrenone 用于心力衰竭和慢性肾病的研究。

生物活性

Balcinrenone (AZD9977) is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. Balcinrenone is used for heart failure, and chronic kidney disease research.

性状

Solid

体外研究(In Vitro)

Balcinrenone (AZD9977) and eplerenone activities on MR, GR, PR and AR in binding assays. The observed pKi of MR, GR, and PR are 7.5, 5.4 and 4.6, respectively.
Functional interaction of Balcinrenone with MR is characterized in a reporter gene assay where the full-length MR drives a luciferase reporter gene in U2-OS cells. Balcinrenone antagonizes aldosterone-activated MR with an IC50 of 0.28 μM. Whereas eplerenone is a full antagonist, Balcinrenone suppresses only 69% of the MR activity in this assay.
Species selective potencies of Balcinrenone are established in reporter gene assays using the MR LBDs from human, mouse or rat. The corresponding IC50 values are 0.37 μM, 0.08 μM and 0.08μM, respectively.
has not independently confirmed the accuracy of these methods.

体内研究(In Vivo)

Balcinrenone (AZD9977) (oral administration; 10-100 mg/kg; 4 weeks) dose dependently reduces the UACR compared to vehicle in uni-nephrectomised male Sprague Dawley rats administered aldosterone and fed a high-salt diet. Balcinrenone is as efficacious as full MR antagonists on renal protection, despite the partial antagonism observed in in vitro assays.
Balcinrenone (oral administration; 100 mg/kg; co-administration with enalapril) stops further disease progression and reduces the urine albumin excretion (UAE) compared to vehicle treatment. Co-administration of enalapril has an apparent additive effect on UAE reduction, although this reduction is not statistically significant.
has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Fredrik Erlandsson, et al. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. Br J Clin Pharmacol. 2018 Jul;84(7):1486-1493.

溶解度数据	In Vitro: DMSO : 250 mg/mL (625.99 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation